Search Results

There are 1665 results for: content related to: A semi-mechanistic absorption model to evaluate drug–drug interaction with dabigatran: application with clarithromycin

  1. You have free access to this content
    The Pharmacology and Therapeutic Use of Dabigatran Etexilate

    The Journal of Clinical Pharmacology

    Volume 53, Issue 1, January 2013, Pages: 1–13, Spinler Sarah

    Version of Record online : 24 JAN 2013, DOI: 10.1177/0091270011432169

  2. Dabigatran etexilate: What do hospitalists need to know?

    Journal of Hospital Medicine

    Volume 7, Issue 3, March 2012, Pages: 262–269, Amer Zeidan, Bishoy Faltas and Michael Streiff

    Version of Record online : 29 NOV 2011, DOI: 10.1002/jhm.996

  3. You have free access to this content
    A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time

    British Journal of Clinical Pharmacology

    Volume 78, Issue 3, September 2014, Pages: 599–609, Paul K. L. Chin, Daniel F. B. Wright, David M. Patterson, Matthew P. Doogue and Evan J. Begg

    Version of Record online : 21 AUG 2014, DOI: 10.1111/bcp.12364

  4. You have free access to this content
    Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

    British Journal of Clinical Pharmacology

    Volume 74, Issue 3, September 2012, Pages: 490–500, Sebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, Gerhard Nehmiz, Ute Lemke, Wolfgang Timmer and Paul A. Reilly

    Version of Record online : 6 AUG 2012, DOI: 10.1111/j.1365-2125.2012.04218.x

  5. An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis

    The Journal of Clinical Pharmacology

    Volume 54, Issue 8, August 2014, Pages: 901–909, Jo-Anne S. Wilson, Kerry B. Goralski, Steven D. Soroka, Matthew Morrison, Paula Mossop, Lekha Sleno, Yan Wang and David R. Anderson

    Version of Record online : 28 MAY 2014, DOI: 10.1002/jcph.335

  6. Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis—A simulation analysis

    The Journal of Clinical Pharmacology

    Volume 56, Issue 5, May 2016, Pages: 597–608, Karl-Heinz Liesenfeld, Fredrik Gruenenfelder and Andreas Clemens

    Version of Record online : 5 NOV 2015, DOI: 10.1002/jcph.620

  7. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin

    The Journal of Clinical Pharmacology

    Volume 52, Issue 2, February 2012, Pages: 243–250, Dr Joachim Stangier, Ms Hildegard Stähle, Dr Karin Rathgen, Dr Willy Roth, Dr Kathrin Reseski and Dr Thomas Körnicke

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010393342

  8. You have full text access to this OnlineOpen article
    Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

    International Journal of Clinical Practice

    Volume 67, Issue 6, June 2013, Pages: 516–526, K. Huber, S. J. Connolly, A. Kher, F. Christory, G.-A. Dan, R. Hatala, R. G. Kiss, B. Meier, B. Merkely, B. Pieske, T. Potpara, J. Stępińska, N. Vene Klun, D. Vinereanu and P. Widimský

    Version of Record online : 5 APR 2013, DOI: 10.1111/ijcp.12147

  9. You have free access to this content
    Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran

    British Journal of Clinical Pharmacology

    Volume 78, Issue 3, September 2014, Pages: 630–638, Paul K. L. Chin, David M. Patterson, Mei Zhang, Berit P. Jensen, Daniel F. B. Wright, Murray L. Barclay and Evan J. Begg

    Version of Record online : 21 AUG 2014, DOI: 10.1111/bcp.12366

  10. You have free access to this content
    Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation

    Clinical Cardiology

    Volume 37, Issue 1, January 2014, Pages: 32–47, Irene Savelieva and A. John Camm

    Version of Record online : 19 NOV 2013, DOI: 10.1002/clc.22204

  11. You have free access to this content
    The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

    British Journal of Clinical Pharmacology

    Volume 64, Issue 3, September 2007, Pages: 292–303, Joachim Stangier, Karin Rathgen, Hildegard Stähle, Dietmar Gansser and Willy Roth

    Version of Record online : 15 MAY 2007, DOI: 10.1111/j.1365-2125.2007.02899.x

  12. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 10, October 2015, Pages: 1790–1798, C. Chai-Adisaksopha, C. Hillis, W. Lim, K. Boonyawat, K. Moffat and M. Crowther

    Version of Record online : 29 SEP 2015, DOI: 10.1111/jth.13117

  13. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

    The Journal of Clinical Pharmacology

    Volume 48, Issue 12, December 2008, Pages: 1411–1419, Dr Joachim Stangier, Hildegard Stähle, Dr Karin Rathgen, Dr Willy Roth and Dr Kasra Shakeri-Nejad

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008324179

  14. You have free access to this content
    Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels

    Journal of Thrombosis and Haemostasis

    Volume 11, Issue 8, August 2013, Pages: 1493–1502, E. M. Hawes, A. M. Deal, D. Funk-Adcock, R. Gosselin, C. Jeanneret, A. M. Cook, J. M. Taylor, H. C. Whinna, A. M. Winkler and S. Moll

    Version of Record online : 14 AUG 2013, DOI: 10.1111/jth.12308

  15. Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the FDA Adverse Event Reporting System during the First Year of Approval

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 6, June 2014, Pages: 561–569, Kevin W. McConeghy, Adam Bress, Dima M. Qato, Coady Wing and Edith A. Nutescu

    Version of Record online : 18 MAR 2014, DOI: 10.1002/phar.1415

  16. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 11, November 2015, Pages: 2087–2092, M. Jacquemin, J. Toelen, J. Schoeters, I. van Horenbeeck, I. Vanlinthout, M. Debasse, M. Peetermans, T. Vanassche, K. Peerlinck, J. van Ryn and P. Verhamme

    Version of Record online : 5 OCT 2015, DOI: 10.1111/jth.13138

  17. Thrombin inhibitors: surgical considerations and pharmacology

    ANZ Journal of Surgery

    Volume 83, Issue 4, April 2013, Pages: 215–221, Omar Breik, Rami Tadros and Peter Devitt

    Version of Record online : 6 FEB 2013, DOI: 10.1111/ans.12078

  18. You have free access to this content
    Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

    Arthritis & Rheumatism

    Volume 63, Issue 5, May 2011, Pages: 1416–1425, Galina S. Bogatkevich, Anna Ludwicka-Bradley, Paul J. Nietert, Tanjina Akter, Joanne van Ryn and Richard M. Silver

    Version of Record online : 27 APR 2011, DOI: 10.1002/art.30255

  19. New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation

    Journal of Cardiovascular Electrophysiology

    Volume 22, Issue 8, August 2011, Pages: 948–955, JUAN F. VILES-GONZALEZ, VALENTIN FUSTER and JONATHAN L. HALPERIN

    Version of Record online : 10 JUN 2011, DOI: 10.1111/j.1540-8167.2011.02104.x

  20. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 555–565, Dr Joachim Stangier, Dr Bengt I. Eriksson, Dr Ola E. Dahl, Dr Lennart Ahnfelt, Dr Gerhard Nehmiz, Hildegard Stähle, Dr Karin Rathgen and Dr Robbyna Svärd

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005274550